The 2024 ASHP Midyear Clinical Meeting made one thing clear: artificial intelligence is no longer a theoretical tool for pharmacy. It is actively being deployed in community pharmacies, hospital systems, and research labs with measurable results.
The data emerging from early adopters is compelling. Community pharmacies using AI-assisted dispensing platforms reported a 40% increase in medication adherence among their patient populations and a 55% reduction in missed refills. These are not marginal improvements. They represent a fundamental shift in how pharmacies manage patient outcomes.
AI in Prescription Review
CVS Health launched an AI-powered prescription review system across select locations, and the early numbers are striking. The system reduced dispensing errors by 78% compared to traditional pharmacist-only review workflows.
The AI does not replace the pharmacist. It functions as a second set of eyes, flagging potential drug interactions, dosing errors, duplicate therapies, and contraindications before the prescription reaches the verification stage. Pharmacists still make the final decision, but they do so with AI-generated alerts that highlight the most critical issues.
This approach addresses a persistent problem in pharmacy: cognitive overload. A busy pharmacist filling hundreds of prescriptions per day cannot realistically catch every potential issue through manual review alone. AI excels at pattern recognition across large datasets, making it well suited to this task.
Predicting Adverse Events Before They Happen
Researchers at the Stanford AI Lab presented findings showing their model achieved 89% accuracy in predicting rare adverse drug events. The model was trained on millions of electronic health records and prescription data points, allowing it to identify patterns that human reviewers would likely miss.
Rare adverse events are particularly dangerous because they are, by definition, uncommon. A pharmacist might encounter a specific drug-gene interaction once in a career. An AI model trained on population-level data can flag that risk every time it appears.
This predictive capability has significant implications for pharmacogenomics. As genetic testing becomes more accessible, AI systems that can cross-reference a patient's genetic profile with their medication list will become increasingly valuable in preventing adverse reactions.
Medication Adherence and Refill Management
Non-adherence to prescribed medications costs the North American healthcare system billions of dollars annually and contributes to preventable hospitalizations and deaths. AI is proving effective at addressing this problem through several mechanisms.
Predictive refill alerts. AI systems analyze a patient's refill history and identify patterns that suggest they are likely to miss an upcoming refill. The pharmacy can then proactively reach out with reminders or offer delivery options.
Personalized communication. Rather than sending generic reminders, AI can tailor messages based on a patient's communication preferences, language, and engagement history. Patients who respond better to text messages get texts. Those who prefer phone calls get calls.
Intervention prioritization. Not all non-adherent patients carry the same risk. AI helps pharmacies focus their outreach efforts on patients whose non-adherence is most likely to result in hospitalization or adverse outcomes.
Practical Considerations for Canadian Pharmacies
Canadian pharmacies considering AI adoption should evaluate several factors.
Data privacy compliance. Any AI system processing patient data must comply with PIPEDA at the federal level and applicable provincial privacy legislation such as Ontario's PHIPA. Pharmacies should ensure that AI vendors can demonstrate compliance and that patient data is not used for purposes beyond the stated clinical objectives.
Integration with existing systems. AI tools need to work with the pharmacy management software already in use. Standalone AI products that require separate data entry or do not integrate with dispensing workflows will create friction rather than efficiency.
Staff training. AI is a tool, not a replacement. Pharmacists and technicians need training on how to interpret AI-generated alerts, when to override them, and how to document their clinical decisions.
Cost and ROI. AI platforms range from affordable cloud-based subscriptions to expensive enterprise deployments. Pharmacies should evaluate the return on investment in terms of error reduction, adherence improvements, and time savings rather than technology features alone.
The Road Ahead
AI in pharmacy is moving from pilot programs to standard practice. The pharmacies that adopt these tools early, with proper safeguards and training, will be better positioned to deliver safer, more efficient care. The technology is ready. The question now is how quickly the profession will embrace it.